Barclays PLC Has $34,000 Stock Position in Renovaro Inc. (NASDAQ:RENB)

Barclays PLC increased its stake in Renovaro Inc. (NASDAQ:RENB) by 315.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 69,531 shares of the company’s stock after acquiring an additional 52,804 shares during the quarter. Barclays PLC’s holdings in Renovaro were worth $34,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Rhumbline Advisers acquired a new position in shares of Renovaro in the second quarter worth approximately $79,000. State Street Corp lifted its stake in shares of Renovaro by 3.8% in the third quarter. State Street Corp now owns 1,323,832 shares of the company’s stock worth $640,000 after acquiring an additional 48,114 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in shares of Renovaro in the second quarter worth approximately $220,000. 71.41% of the stock is owned by institutional investors and hedge funds.

Renovaro Price Performance

Renovaro stock opened at $0.79 on Friday. The stock’s 50 day moving average is $0.97 and its 200 day moving average is $0.87. The firm has a market cap of $125.77 million, a P/E ratio of -0.83 and a beta of 0.65. Renovaro Inc. has a one year low of $0.40 and a one year high of $5.25.

Renovaro (NASDAQ:RENB) last posted its quarterly earnings data on Thursday, October 10th. The company reported ($0.45) EPS for the quarter.

Renovaro Company Profile

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.